Status:
WITHDRAWN
Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.
Lead Sponsor:
Pfizer
Conditions:
Neovascular Age-related Macular Degeneration
Eligibility:
All Genders
50+ years
Brief Summary
An open label, non-comparative, multicenter, non-interventional, post marketing surveillance study to evaluate the overall safety and tolerability of pegaptanib sodium(Macugen) in the treatment of Fil...
Detailed Description
Open-label, non-comparative, non-interventional study
Eligibility Criteria
Inclusion
- Must have at least one eye which was diagnosed with neovascular degeneration
Exclusion
- Presence of other causes of choroidal neovascularization, including pathologic myopia (spherical equivalent of -8 diopters or more negative, or axial length of 25mm or more), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, multifocal choroiditis
Key Trial Info
Start Date :
February 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00820742
Start Date
February 1 2008
End Date
May 1 2009
Last Update
March 5 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.